Yale: Tiziana Life Sciences Ltd.: Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial
NEW YORK, March 25, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully...
Read full article »
Yale is a Connecticut-based educational institution that offers degree programs in disciplines such as liberal arts, engineering and medicine for students.
Read more